NLRP3 and type 2 diabetes mellitus: Recently, it has been reported that tranilast, which is an old and safe clinic drug, could selectively and potently inhibit the NLRP3 inflammasome activation and is effective in mouse models of gout and T2D (52), while the therapeutic effect of tranilast needs to be further evaluated in clinical trials.